A double-blind two part placebo-controlled study consisting of a single ascending and multiple-dose tolerance study of peroral insulin in patients with Type 2 diabetes

BOWS Pharmaceuticals AG0 个研究点开始时间: 2009年2月24日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male and female subjects with Type 2 diabetes who were diagnosed for a minimum of 6 months, age 30-65 years.
•2. Subjects on a stable dose of metformin for at least two months with a total daily dose of = 2600 mg/day.
•3. Subjects demonstrating an insulin resistance value (IR) higher than 3 based on the HOMA-2 model (University of Oxford, 2004) at Screening 2.
•4. Hemoglobin A1c <9%.
•5. Fasting capillary blood glucose within the range 6.0-9.0 mmol/L (108-162 mg/dL) at Screening 1, Screening 2 and Randomization visit. For study Part 1 only, the maximum and minimum of these three measurements may not differ by more than 2 mmol/L. However, the subject should not be excluded from the study if the capillary blood glucose is out of this range once oral insulin dosing has started.
•6. Body Mass Index (BMI) of 25-32 kg/m2
•7. Medically stable as determined by history and physical examination, including vital signs.
•8. Screening laboratory tests must be within normal range or judged as not clinically significant by Principal investigator/Subinvestigator.
•9. Negative urine ketoacidosis test
•10. ECG including QTcB shows no clinically significant abnormality or acute ischemia
•11. Supine BP = 160/100 mm Hg diastolic/systolic.
•12. Able to adhere to the study visit schedule, and to understand and comply with other protocol requirements.
•13. Capable of giving informed consent, which must be obtained prior to any screening procedures.
•14. Non user of tobacco products for a minimum of 6 months prior to the first dose.
•15. Negative urine screen for drugs of abuse and an alcohol breath test at screening and check in.
•16. Negative laboratory screen for Hepatitis B (HBsAg and anti-HBc antibodies), Hepatitis C (anti HCV) and HIV (1&2).
•17. Willing to refrain from consuming alcohol 24 hours prior to dosing and throughout the period of sample collection.
•18. Willing to refrain from consuming grapefruit (in food or as juice) 7 days prior to the first dose and throughout the period of sample collection.
•19. Not on any prohibited medication
•20. Female subjects willing to use adequate method of contraception from the time of the first dose until one month after the last dose.
•21. Willing to eat standard meal in accordance with the protocol.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•1. History of significant coronary disease or renal failure
•2. Other significant medical problems that would preclude participation in a clinical trial
•3. Participation in a clinical trial within the prior 3 months
•4. History of GI surgery or known GI motility disorders.
•5. History of a serious infection, including but not limited to hepatitis, pneumonia, or pyelonephritis, or have been hospitalized or received intravenous antibiotics for an infection, during the previous two months.
•6. A chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (bronchiectasis), sinusitis, recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), open skin wound, or ulcer.
•7. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine (other than diabetes), pulmonary, cardiac, neurologic, or cerebral disease, or any other condition which increases risk of participation in this trial in the opinion of the investigator.
•8. Currently known malignancy or a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been excised more than one year ago with no evidence of recurrence.
•9. History of polyps in the gastrointestinal tract
•10. Known to have had a substance abuse (drug or alcohol) problem within the previous 5 years
•11. Unable to undergo venipunctures for study purposes because of poor tolerability or lack of easy access.
•12. Engaging in any strenuous exercise (such as running or weight lifting or playing any team sports such as soccer for 48 hours prior to admission to the inpatient unit and no strenuous exercise will be permitted for the duration of the study (applies to both part 1 and part 2).
•13. Donation or loss of 400ml blood or more within 3 months prior to the first dose.
•14. Donation of plasma within 7 days prior to the first dose.
•15. Difficulty in swallowing capsules.
•16. A recent adult history of clinically significant allergic reaction to any drug.
•17. Any other medical condition that, in the opinion of the investigator, disqualifies the subject.
•18. Female subject with positive pregnancy test at screening, Day -1.

研究者

发起方

BOWS Pharmaceuticals AG

相似试验

进行中（未招募）

1 期

A study of the safety, pharmacokinetics and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndromeDravet SyndromeMedDRA version: 18.0 Level: PT Classification code 10073677 Term: Severe myoclonic epilepsy of infancy System Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2014-000995-24-GBGW Research Ltd154

进行中（未招募）

不适用

A study of the safety, pharmacokinetics and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome

EUCTR2014-000995-24-PLGW Research Ltd125

已完成

不适用

A study to find the difference in bioavailability of 3 different ingredients through FenuMAT delivery system and its comparison with natural existing forms.

CTRI/2018/03/012753Akay Flavours and Aromatics Private Limited45

已完成

不适用

A study to find the increase in bioavailability of 2 different ingredients through FenuMAT delivery system and its comparison with natural existing forms.

CTRI/2018/03/012875Akay Flavours and Aromatics Private Limited30

进行中（未招募）

不适用

EUCTR2010-021983-14-BEZ Gasthuisberg30